Results 31 to 40 of about 97,803,787 (197)

Altered expression of vascular endothelial growth factor, vascular endothelial growth factor receptor-1, vascular endothelial growth factor receptor-2, and Soluble Fms-like Tyrosine Kinase-1 in peripheral blood mononuclear cells from normal and preeclamptic pregnancies

open access: yesChinese Journal of Physiology, 2019
Preeclampsia (PE) is the leading cause of maternal and fetal morbidity and mortality. It complicates around 2%–10% pregnancies worldwide due to imbalance between proangiogenic and anti-angiogenic factors, leading to incomplete placentation, ischemia, and
Zaima Ali   +4 more
doaj   +1 more source

The role of heterodimerization between VEGFR-1 and VEGFR-2 in the regulation of endothelial cell homeostasis [PDF]

open access: yes, 2012
VEGF-A activity is tightly regulated by ligand and receptor availability. Here we investigate the physiological function of heterodimers between VEGF receptor-1 (VEGFR-1; Flt-1) and VEGFR-2 (KDR; Flk-1) (VEGFR(1-2)) in endothelial cells with a synthetic ...
Cudmore, Melissa J.   +21 more
core   +1 more source

Elucidating activation and deactivation dynamics of VEGFR-2 transmembrane domain with coarse-grained molecular dynamics simulations

open access: yesPLoS ONE, 2023
The vascular endothelial growth factor receptor 2 (VEGFR-2) is a member of receptor tyrosine kinases (RTKs) and is a dimeric membrane protein that functions as a primary regulator of angiogenesis.
Yeon Ju Go   +2 more
doaj   +2 more sources

Differential expression of Vegfr-2 and its soluble form in preeclampsia.

open access: yesPLoS ONE, 2012
BackgroundSeveral studies have suggested that the main features of preeclampsia (PE) are consequences of endothelial dysfunction related to excess circulating anti-angiogenic factors, most notably, soluble sVEGFR-1 (also known as sFlt-1) and soluble ...
Carine Munaut   +10 more
doaj   +1 more source

Cooperative and redundant roles of VEGFR-2 and VEGFR-3 signaling in adult lymphangiogenesis [PDF]

open access: yes, 2007
Activation of vascular endothelial growth factor ( VEGF) receptor-3 (VEGFR-3) by VEGF-C initiates lymphangiogenesis by promoting lymphatic proliferation and migration.
Cui, Yingjie   +19 more
core   +1 more source

Molecular Docking Approach of Some Quinoxaline Derivatives as Anticancer Agents Targeting VEGFR-2. [PDF]

open access: yesAlfarama Journal of Basic & Applied Sciences
The vascular endothelial growth factor receptor-2 (VEGFR-2) has a crucial role in the angiogenesis of cancer. The growth of tumors was effectively prevented by inhibiting the VEGFR-2 regulatory pathway.
Lamiaa Barakat   +3 more
doaj   +1 more source

Novel 3-phenylquinazolin-2,4(1H,3H)-diones as dual VEGFR-2/c-Met-TK inhibitors: design, synthesis, and biological evaluation

open access: yesScientific Reports, 2023
Multitarget anticancer drugs are more superior than single target drugs regarding patient compliance, drug adverse effects, drug-drug interactions, drug resistance as well as pharmaceutical industry economics.
Abdelfattah Hassan   +4 more
doaj   +1 more source

The Effects of VEGF Signal Pathway on Etiopathogenesis and AntiVEGF Treatments in Childhood Cancers

open access: yesÇocuk Dergisi, 2023
Vascular endothelial growth factor (VEGF) is the most physiologically and pathologically potent angiogenic factor that acts directly on endothelial cells.
Ali Kazdal   +3 more
doaj   +1 more source

Lv-vegfr-10-Ig expression during BC transfating.

open access: yes, 2019
(A) Control gastrula. Lv-vegfr-10-Ig is expressed at high levels by PMCs (arrow), as previously reported [9]. (B) PMC(−) embryo, 2 hpd. Expression of Lv-vegfr-10-Ig is evident in the invaginating vegetal plate (arrow), a region that includes presumptive ...
Ashrifia Adomako-Ankomah (7401002)   +1 more
core   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

open access: yesMolecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy